Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (NCT05740566)

🧪 Interventions in This Study

• Tarlatamab (DRUG)
• Lurbinectedin (DRUG)
• Topotecan (DRUG)
• Amrubicin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (223 Sites)

Showing the first 25 of 223 sites.

• University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
• Alaska Oncology and Hematology — Anchorage, Alaska
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• University of California Los Angeles — Santa Monica, California
• Northwestern University — Chicago, Illinois
• University of Illinois Chicago — Chicago, Illinois
• Indiana University — Indianapolis, Indiana
• University of Iowa — Iowa City, Iowa
• Pikeville Medical Center — Pikeville, Kentucky
• Our Lady of the Lake Cancer Institute — Baton Rouge, Louisiana
• Trinity Health Saint Joseph Mercy Ann Arbor — Ann Arbor, Michigan
• University of Minnesota Cancer Center — Minneapolis, Minnesota
• University of Missouri Health Care — Columbia, Missouri
• Summit Medical Group, Overlook Oncology Center — Summit, New Jersey
• New York University Grossman School of Medicine and New York University Langone Hospitals — New York, New York
• Perlmutter Cancer Center at New York University Langone Hospital----Long Island — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Northport Veterans Affairs Medical Center — Northport, New York
• Sanford Roger Maris Cancer Center — Fargo, North Dakota
• Sanford Oncology Clinic and Pharmacy — Sioux Falls, South Dakota
• University of Tennessee Medical Center Knoxville — Knoxville, Tennessee
• Baptist Cancer Center — Memphis, Tennessee
• Virginia Commonwealth University — Richmond, Virginia
• Swedish Cancer Institute Medical Oncology — Edmonds, Washington
• The Medical College of Wisconsin — Milwaukee, Wisconsin

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Small Cell Lung Cancer (SCLC)

• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC — Los Angeles, California
• Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer — Fayetteville, Arkansas
• Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer — Chicago, Illinois
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) — Duarte, California
• DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy — Mobile, Alabama

Explore by condition: All Small Cell Lung Cancer (SCLC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.